Players of the coronavirus vaccine are on duty this morning before the results of the Phase 1 trial of AstraZeneca (NYSE: AZN) The COVID-19 vaccine developed with the University of Oxford, to be published in The lancet.
Reports last week suggested the magazine would release positive news: The vaccine is believed to be in one of the most advanced stages of clinical trials. “Tomorrow. Shots. I’m just saying,” Lancet Editor Richard Horton tweeted on Sunday.
Overnight, the UK secured early access to 90M doses of developing vaccines by drug manufacturers, including Pfizer (NYSE: PFE), BioNTech (NASDAQ: BNTX) and Valneva (OTC: INRLF), while GlaxoSmithKline signed an agreement with CureVac to develop vaccines and antibodies based on mRNA.
According to the World Health Organization, in just six months since the coronavirus outbreak, 140 vaccine candidates are in the preclinical testing stage and 23 have entered the clinical evaluation stage.
In the United States, there is mistrust of an approved vaccine, and a recent survey found that only 50% of people say they would be willing to receive it.
Related tickers: Pfizer (PFE) + 3%, BioNTech (BNTX) + 5.9%. Novavax (NASDAQ: NVAX) + 4.8%, Inovio Pharmaceuticals (NASDAQ: INO) + 2.1%; Modern (NASDAQ: MRNA) + 0.7%; AstraZeneca (AZN) (-1.9%), Dynavax (NASDAQ: DVAX) (+ 7.0%), GlaxoSmithKline (NYSE: GSK) (-1.2%), iBio (NYSEMKT: IBIO) (+ 30.0%), Inovio Pharmaceuticals (INO) (+ 3.8%), Altimmune (NASDAQ: ALT) (+ 4.5%), VBI vaccines (NASDAQ: VBIV) (+ 3.7%), Pfizer (PFE) (+ 3.9%)
AstraZeneca shares have risen more than 20% in the past 6 months.
